Versant Ventures Wagers $35M on Cytokine Engineering with Bright Peak

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Abdera Gets $142M To Make Potent, Safe, Radioantibodies for Cancer
Belharra Gets $130M from Versant, Genentech For Chemoproteomic Discovery
Red Tree Debuts With $272M, Zeroing In On West Coast Startups
Versant-backed Cimeio Gets $50M for Shielded Stem Cell Therapies